Korean pharmaceuticals manufacturer Samsung Biologics boosted earnings ahead of its 2016 IPO by reclassifying its joint venture Samsung Bioepis from a subsidiary to an associate, booking a large one-off revaluation gain. This is a proven fraud as the Korean Securities and Futures Commission found that the company had deliberately broken accounting rules.

The information on this page has been compiled from publicly available sources. GMT Research Limited has not verified the information and does not warrant its accuracy. Any claims made or views expressed are not necessarily those of GMT Research Limited.